An observational study in Diabete Type 2, Regurgitation and Pulmonary Aspiration During Anaesthetic Induction, sponsored by University Hospital, Geneva. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-01.
Sponsored by University Hospital, Geneva · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 112 studies in Diabetes Mellitus, Type 2 with a site in Switzerland — 13 open to participants now, 18 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Switzerland.
Among the 112 studies in Diabetes Mellitus, Type 2 with a site in Switzerland, this one is the 20th largest by planned enrollment of the 21 observational ones that give a count, is one of 4 that started in 2026, is one of 21 observational ones, reaches primary completion later than 5 of the 17 other live ones, and was the 110th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →13 of the 112 studies in Diabetes Mellitus, Type 2 with a site in Switzerland are open now. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in Switzerland, United States, Argentina and 48 more countries
Ages 18+
Heba Al-Alwan · Sites in Switzerland
Ages 18+
University of Cambridge · Sites in Switzerland, Australia, Austria and 3 more countries
Ages 18+
Marc Donath · Sites in Switzerland, Belgium, France and 1 more country
Ages 18–75
Dr. Med Anas Taha · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
112 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 51 · Phase 4 9
First in 1998; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 38 is below the median of 300 across 1,749 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 330 across the 91 interventional studies, 450 across the 21 observational. Of the 89 that completed or were terminated, 24 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 112 have an industry lead sponsor. The 10 most frequent:
University Hospital, Geneva is the lead sponsor of 379 studies on the registry; 70 are open to participants now.
University Hospital, Geneva has 3 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
5 of the studies in Diabetes Mellitus, Type 2 with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT06715514Lia BallyMenopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Overweight/Obesity and Impaired Glucose Homeostasis | 2026-12-17 |
| NCT07506356University Hospital, GenevaInvestigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors | 2026-12-31 |
| NCT06579404University of CambridgeClosed-loop in Adults With Type 2 Diabetes | 2027-03 |
| NCT06925217Heba Al-AlwanClosed-Loop Impact on Chronic Kidney Disease in Type 2 Diabetes | 2027-05 |
Add all 5 to your calendar (.ics) → With an account.
Among the 112 studies in Diabetes Mellitus, Type 2 with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Treatment with semaglutide slows down gastric emptying , food remains in the stomach for a longer period of time. This slowing has important implications for anesthesia management. At present, we do not know the optimal duration for discontinuing this medication before surgery and anesthesia to ensure an empty stomach.
This is an observational research project, conducted exclusively at the Geneva University Hospitals (HUG). To answer the research question, participation of 38 individuals will be required. The duration of participation for each person is 7 days.
To recruit the necessary number of participants, approximately 1.5 years will be needed.
This project is being carried out in accordance with Swiss legal requirements and recognized international guidelines. The competent ethics committee has reviewed and approved this project.
The project will last 7 day during which the participants will need to come 3 times at the hospital to make gastric ultrasounds. On these days the participants will be asked to have a breakfast between 7 and 8 am including a minimum of bread and/or cereals and/or proteins. After that the participants will be asked to fast for 6 hours for solide food and 2 hours for liquids. If the participants smokes, they must for 12h before the exam.
At 2Pm an anesthesiologist will welcome the participant to make the exam at the hospital to evaluate the gastric volume after what the participants will be able to get a small collation and go back home.
Diabetic patients treated by GLP-1 analog
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A safe gastric volume for anesthesia in diabetic patients treated with GLP-1 analog after a 6 hours fasting period 7 day after the last injection.
Our primary objective is to show that after a fasting period of 6 hours, seven days after the last injection of GLP-1, gastric volume of diabetic patients is safe for anaesthesia. Our hypothesis is that seven days after the last injection of GLP-1, and after a 6h fasting period, the mean gastric volume of treated patients will be lower than 1.5 ml/kg, corresponding to the most accepted volume threshold of an at risk (full) stomach
Time frame: 1 week
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Dec 2026, 8 months later.
Of 436 non-industry observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 96. This study's planned 8 months is below that.
Counting every sponsor, half of 606 studies reached it within 32 months; a quarter within 17 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.